<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482390</url>
  </required_header>
  <id_info>
    <org_study_id>NV27779</org_study_id>
    <secondary_id>2011-002715-28</secondary_id>
    <nct_id>NCT01482390</nct_id>
  </id_info>
  <brief_title>A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Telaprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment With Pegylated Interferon/Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, multi-center, parallel-group study will evaluate the sustained
      virologic response and the safety of mericitabine (RO5024048) (MCB) in combination with
      telaprevir (TVR) and peginterferon Alfa-2a (PEG-IFN) / ribavirin (RBV) in participants with
      chronic Hepatitis C infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2011</start_date>
  <completion_date type="Actual">January 31, 2014</completion_date>
  <primary_completion_date type="Actual">January 31, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Sustained Virological Response 12 Weeks After End of Treatment (SVR12), as Determined by Polymerase Chain Reaction (PCR) Using Roche COBAS TaqMan Hepatitis C Virus (HCV) Test</measure>
    <time_frame>12 weeks after end of treatment (up to Week 60)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response 4 Weeks After End of Treatment (SVR-4), as Determined by PCR Using Roche COBAS TaqMan HCV Test</measure>
    <time_frame>4 weeks after end of treatment (up to Week 52)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virological Response 24 Weeks After End of Treatment (SVR-24), as Determined by PCR Using Roche COBAS TaqMan HCV Test</measure>
    <time_frame>24 weeks after end of treatment (up to Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virological Response Over Time From Week 2 to Week 48, as Determined by PCR Using Roche COBAS TaqMan HCV Test</measure>
    <time_frame>Weeks 2, 4, 12, 24, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment- Resistant Mutations, as Determined Using Standard Sequencing Technology</measure>
    <time_frame>Baseline up to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HCV Ribonucleic Acid (RNA) Levels</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, 52, 60, and 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Event</measure>
    <time_frame>Baseline up to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration of RO4995855 (Parent Drug of Mericitabine)</measure>
    <time_frame>Pre-dose (-0.5 hour) on Day 1 and Week 8; 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hour post dose in Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration of Metabolite of RO4995855 (RO5012433)</measure>
    <time_frame>Pre-dose (-0.5 hour) on Day 1 and Week 8; 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hour post dose in Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration of Telaprevir</measure>
    <time_frame>Pre-dose (-0.5 hour) on Day 1 and Week 8; 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12 hour post dose in Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than [&lt;] 75 kg) or 1200 mg (for participants weighing greater than or equal to [&gt;=] 75 kg) orally for 24 or 48 weeks.</description>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)</arm_group_label>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)</arm_group_label>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_label>TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mericitabine</intervention_name>
    <description>Participants will receive mericitabine 1000 mg orally twice daily.</description>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)</arm_group_label>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)</arm_group_label>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2a</intervention_name>
    <description>Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.</description>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)</arm_group_label>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)</arm_group_label>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_label>TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matching to mericitabine orally twice daily.</description>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_label>TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Participants will receive telaprevir 750 mg orally three times daily.</description>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)</arm_group_label>
    <arm_group_label>TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)</arm_group_label>
    <arm_group_label>TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)</arm_group_label>
    <arm_group_label>TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C infection for at least 6 months duration

          -  Hepatitis C genotype 1a or 1b

          -  Participants must have discontinued prior hepatitis C treatment at least 12 weeks
             prior to enrollment in this study

          -  Participants showed a previous null response to therapy as defined by &lt; 2 logarithm to
             the base 10 (log10) international units per milliliter (IU/mL) decrease in viral titer
             after at least 12 weeks of treatment with PEG-IFN/RBV

        Exclusion Criteria:

          -  Hepatitis C infection with a genotype other than genotype 1a or 1b

          -  Body mass index &lt; 18 or &gt;= 36 kilograms per square meters (kg/m^2)

          -  Hepatitis A, hepatitis B, or human immunodeficiency virus (HIV) infection

          -  Herbal remedies &lt;=1 month prior to the first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Gastro Associates, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrowest Medical Center</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Gastroenterology &amp; Hepatology; Clinical Research Unit</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina'S Center For Liver Disease</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of Cincinnati College of Medicine; Div. of Digestive Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Uni Medical Center; Division Of Hepatology/Transplantation; Annette C. and Harold C. Simmons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire; Veteran Affairs Med Ctr</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Leslie Diamond Health Care Centre; Dept. of Medicine - Division of Gastroenterology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute; Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research Ltd.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Regional Health Authority; Section of Hepatology</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto Western Hospital; Hepatology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digest. Disease Asso.</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University, Montreal Chest Institute; Viral and other Infectious</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez;Gastro Enterologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Hopital Saint Joseph; Gastro-Enterologie</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan;Gastro Enterologie Hepatologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Freiburg; Abteilung Innere Medizin II</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts Klinikum; Schleswig-Holstein Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Divisione Malattie Infettive</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cisanello - Az. Osp. Pisana; Unità Operativa Di Gastroenterologia Ed Epatologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias; Servicio de Digestivo</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Departamento de Enfermedades Infecciosas</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial; Servicio de Digestivo</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III; Laboratorio de Biologia Molecular</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital, Gastroenterology</name>
      <address>
        <city>Dorset</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King'S College Hospital; Institute of Liver Studies</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust; Hepatology Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <disposition_first_submitted>August 9, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 9, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 11, 2016</disposition_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

